Login to Your Account



Clinic Roundup


Wednesday, May 1, 2013
• Transition Therapeutics Inc., of Toronto, reported results of a five-week proof-of-concept study testing TT-401 in Type II diabetic and obese nondiabetic subjects, showing that once-weekly treatment demonstrated significant improvements in glycemic control and reductions in body weight.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription